Skip to main content
. 2012 Oct 17;2012(10):CD004398. doi: 10.1002/14651858.CD004398.pub3

Fijn 2000.

Methods Study design: ITS
Participants Physicians
Clinical speciality: general practice/family medicine
Level of training: fully trained
Setting/country: not clear/The Netherlands
Interventions The PEM consisted of revised independent Dutch national recommendations on antithrombotic prophylaxis of IHD were introduced in 1996. 2 peer‐reviewed clinical practice guidelines were issued: 1 by the Dutch Institute for Healthcare Improvement, a national scientific authority representing hospital specialists, and 1 by the Dutch Scientific Society of General Practitioners. At the same time, identical recommendations were presented by the Dutch Drug Bulletin Institute and the Health Insurance Fund Council. All of these recommend additional prophylactic antithrombotic therapy, preferably thrombocyte aggregation inhibitors, to existing rescue or maintenance therapy, or both, for acute and chronic IHD
Outcomes 1 process outcome: number of patient who were prescribed antithrombotic therapy after having a diagnosis of IHD
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Intervention independent of other changes ‐ ITS Unclear risk No information was provided
Shape of Intervention effect pre‐specified ‐ ITS Unclear risk Quote, pg. 740: "All of these recommend additional prophylactic antithrombotic therapy, preferably thrombocyte aggregation inhibitors, to existing rescue and/or maintenance therapy for acute and chronic IHD." "this research will evaluate antithrombotic prescribing in newly diagnosed IHD patients in general practice"  
Intervention unlikely to affect data collection ‐ ITS Low risk The intervention did not affect the source (community pharmacies in the InterAction working group) or the method of data collection
Blinding of outcome assessors (detection bias) ‐ ITS 
 All outcomes Low risk The outcome was objective
Incomplete outcome data (attrition bias) ‐ ITS 
 All outcomes Low risk The complete databases from 10 pharmacies were used
Selective reporting (reporting bias) ‐ ITS Low risk All relevant outcomes in the methods section were reported in results section
Other bias ‐ ITS Low risk There was no evidence of other risks of bias